达雷妥尤单抗联合泊马度胺治疗复发难治性多发性骨髓瘤的效果  

Efficacy of Daratumumab Combined with Pomalidomide in the Treatment of Relapsed Refractory Multiple Myeloma

作　　者：张秀秀[1] 张慧 ZHANG Xiuxiu;ZHANG Hui(Hematology Department,Pizhou People's Hospital,Pizhou 221300,China;不详)

机构地区：[1]邳州市人民医院血液科,江苏邳州221300

出　　处：《中国医学创新》2025年第9期64-68,共5页Medical Innovation of China

摘　　要：目的:研究复发难治性多发性骨髓瘤(RRMM)患者联合应用达雷妥尤单抗与泊马度胺治疗的临床效果。方法:选取2019年1月—2022年6月邳州市人民医院收治的60例RRMM患者作为双盲随机对照试验样本,采用随机数字表法分为试验组、对照组,各30例。对照组行包含泊马度胺的基础治疗方案,试验组在对照组基础上增加达雷妥尤单抗治疗。比较两组总缓解率、临床获益率、无进展生存期、总生存期、细胞因子水平及不良反应发生率。结果:试验组总缓解率、临床获益率均高于对照组,无进展生存期、总生存期均长于对照组,差异均有统计学意义(P<0.05)。治疗后,试验组细胞因子水平均低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:RRMM患者联合应用达雷妥尤单抗与泊马度胺治疗效果显著,可延长无进展生存期与总生存期,降低多种细胞因子水平,用药安全性较高。Objective:To study the clinical effect of the combination of Daratumumab and Pomalidomide in patients with relapsed refractory multiple myeloma(RRMM).Method:A total of 60 patients with RRMM admitted to Pizhou People's Hospital from January 2019 to June 2022 were selected as double-blind randomized controlled trial samples,and they were divided into experimental group and control group by random number table method,with 30 cases in each group.The control group received basic treatment including Pomalidomide,and the experimental group was treated with Daratumumab on the basis of the control group.The overall response rate,clinical benefit rate,progression-free survival,overall survival,cytokine levels and incidence of adverse reactions between the two groups were compared.Result:The total remission rate and clinical benefit rate of experimental group were higher than those of control group,and the progression-free survival and overall survival were longer than those of control group,the differences were statistically significant(P<0.05).After treatment,cytokine levels in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion:In RRMM patients,the combination of Daratumumab and Pomalidomide has a significant effect,which can prolong progression-free survival and overall survival,reduce the levels of various cytokines,and has a high drug safety.

关 键 词：达雷妥尤单抗 泊马度胺 多发性骨髓瘤 

分 类 号：R73[医药卫生—肿瘤]